Pathos AI
Pathos AI
eDR87Effective DR: 87/100. Above median. Measured by StartupHub.ai. Median 68.Agent52Agent Readiness: 52/100. Top 25%. Measured by StartupHub.ai. Median 41.clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs
About
clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs
Key facts
At-a-glance profile data
- Website
- pathos.com
- Employees
- 103
- Total funding
- $237M (Series E)
Funding rounds
| Date | Round | Amount | Post-money | Lead investors |
|---|---|---|---|---|
| 23 Oct 2026 | Series E | $237M | $3.0B | Bristol-Myers Squibb |
Tech stack
Detected on pathos.com, last scanned 23 Oct 2026. Run your own scan
- Email provider
- Google Workspace
- Integration capability
- Linear
Add first review
In the news
From the blog
Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology…
Pathos AI · Oct 23, 2026
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Developm…
Pathos AI · Oct 23, 2026
Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer i…
Pathos AI · Aug 4, 2026
Frequently asked
Is Pathos AI trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Pathos AI is 86 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Pathos AI raised?
Pathos AI has raised a total of $237M in funding. The most recent round on record is Series E.
How many employees does Pathos AI have?
Pathos AI has approximately 103 people on record.
